search
Back to results

Removal of mtDNA in Plasma by Continous Venovenous Hemofiltration in Sepsis

Primary Purpose

Intensive Care Unit

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
continous venovenous hemofiltraion
Sponsored by
First People's Hospital of Chenzhou
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Intensive Care Unit focused on measuring Mitochondrial DNA, Sepsis, Continous venovenous hemofiltation, Intensive Care Unit

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Adult septic patients undergoing CRRT

Exclusion Criteria:

  1. Missing vists
  2. transplatation
  3. cancer
  4. aquired immunodeficiency syndrome

Sites / Locations

  • The First Hospital of Chenzhou

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Septic patients require CVVH

Arm Description

continuous venovenous hemofiltration. Continuous renal replacement therapy（CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .Continuous venovenous hemofiltration（CVVH）is the method of chioce for CRRT in critical ill .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index ，decreasing vasopressor requirements，increasing cardiac index and regulating immune dysfunction .

Outcomes

Primary Outcome Measures

Change of mtDNA concentration in plasma
The specimens in the prefilter and postfilter blood as well as in the ultrafiltrate were obtained at the beginning of CRRT (T0) and 6 h (T6h), 12 h (T12h) after the setup of CVVH.

Secondary Outcome Measures

Full Information

First Posted
September 3, 2019
Last Updated
September 5, 2019
Sponsor
First People's Hospital of Chenzhou
search

1. Study Identification

Unique Protocol Identification Number
NCT04083482
Brief Title
Removal of mtDNA in Plasma by Continous Venovenous Hemofiltration in Sepsis
Official Title
Removal of mtDNA in Plasma by Continous Venovenous Hemofiltration in Sepsis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Unknown status
Study Start Date
August 20, 2018 (Actual)
Primary Completion Date
September 20, 2018 (Actual)
Study Completion Date
December 31, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
First People's Hospital of Chenzhou

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The plasma level of mtDNA in sepsis is affected by continous venovenous hemofiltation（CVVH）
Detailed Description
Continous renal replacement therapy （CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .In clinical patients ，continous venovenous hemofoiltration （CVVH）is actually the method of chioce for CRRT in critically ill and hemodynamic instable patients .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index，increasing cardiac index and regulating immune dysfuntion .

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intensive Care Unit
Keywords
Mitochondrial DNA, Sepsis, Continous venovenous hemofiltation, Intensive Care Unit

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Septic patients require CVVH
Arm Type
Experimental
Arm Description
continuous venovenous hemofiltration. Continuous renal replacement therapy（CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .Continuous venovenous hemofiltration（CVVH）is the method of chioce for CRRT in critical ill .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index ，decreasing vasopressor requirements，increasing cardiac index and regulating immune dysfunction .
Intervention Type
Procedure
Intervention Name(s)
continous venovenous hemofiltraion
Intervention Description
CVVH
Primary Outcome Measure Information:
Title
Change of mtDNA concentration in plasma
Description
The specimens in the prefilter and postfilter blood as well as in the ultrafiltrate were obtained at the beginning of CRRT (T0) and 6 h (T6h), 12 h (T12h) after the setup of CVVH.
Time Frame
befor,6hours, 12hours, after CVVH treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adult septic patients undergoing CRRT Exclusion Criteria: Missing vists transplatation cancer aquired immunodeficiency syndrome
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
dixian luo, MS
Organizational Affiliation
Chenzhou First people Hospital
Official's Role
Study Director
Facility Information:
Facility Name
The First Hospital of Chenzhou
City
Chenzhou
State/Province
Hunan
ZIP/Postal Code
450003
Country
China

12. IPD Sharing Statement

Learn more about this trial

Removal of mtDNA in Plasma by Continous Venovenous Hemofiltration in Sepsis

We'll reach out to this number within 24 hrs